Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(100%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated4100%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

NCT06087406
terminatedphase_1

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

NCT06524687
terminatedphase_1

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

NCT06041568
terminatedphase_1

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04082936

Clinical Trials (4)

Showing 4 of 4 trials
NCT06087406Phase 1

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Terminated
NCT06524687Phase 1

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

Terminated
NCT06041568Phase 1

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

Terminated
NCT04082936Phase 1

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4